Enhancement of sodium caprate on intestine absorption and antidiabetic action of berberine.
Berberine, a plant alkaloid used in traditional Chinese medicine, has a wide spectrum of pharmacological actions, but the poor bioavailability limits its clinical use. The present aim was to observe the effects of sodium caprate on the intestinal absorption and antidiabetic action of berberine. The in situ, in vitro, and in vivo models were used to observe the effect of sodium caprate on the intestinal absorption of berberine. Intestinal mucosa morphology was measured to evaluate the toxic effect of sodium caprate. Diabetic model was used to evaluate antidiabetic effect of berberine coadministered with sodium caprate. The results showed that the absorption of berberine in the small intestine was poor and that sodium caprate could significantly improve the poor absorption of berberine in the small intestine. Sodium caprate stimulated mucosal-to-serosal transport of berberine; the enhancement ratios were 2.08, 1.49, and 3.49 in the duodenum, jejunum, and ileum, respectively. After coadministration, the area under the plasma concentration-time curve of berberine was increased 28% than that in the absence of sodium caprate. Furthermore, both berberine and coadministration with sodium caprate orally could significantly decrease fasting blood glucose and improve glucose tolerance in diabetic rats (P < 0.05). The hypoglycemic effect of coadministration group was remarkably stronger, and the areas under the glucose curves was decreased 22.5%, compared with berberine treatment group (P < 0.05). Morphologic analysis indicated that sodium caprate was not significantly injurious to the intestinal mucosa. The study demonstrates that sodium caprate could significantly promote the absorption of berberine in intestine and enhance its antidiabetic effect without any serious mucosal damage.
Lv
Xiao-Yan
XY
Department of Pharmacology, Norman Bethune Medical College, Jilin University, Changchun, Jilin 130021, China.
Li
Jing
J
Zhang
Ming
M
Wang
Chun-Mei
CM
Fan
Zheng
Z
Wang
Chun-Yan
CY
Chen
Li
L
D000042:Absorption / Q000187:drug effects; D000818:Animals; D001599:Berberine / Q000378:metabolism* / Q000494:pharmacology*; D001682:Biological Availability; D003652:Decanoic Acids; D004386:Duodenum / Q000187:drug effects; D007004:Hypoglycemic Agents / Q000378:metabolism / Q000494:pharmacology; D007082:Ileum / Q000187:drug effects; D007408:Intestinal Absorption / Q000187:drug effects*; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism*; D007421:Intestine, Small / Q000187:drug effects*; D007422:Intestines / Q000187:drug effects; D007583:Jejunum / Q000187:drug effects; D008297:Male; D008516:Medicine, Chinese Traditional; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar
D003652:Decanoic Acids; D007004:Hypoglycemic Agents; D001599:Berberine; C031071:decanoic acid